Deciphera Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
DCPH Deciphera Pharmaceuticals Inc
FMO Fiduciary/Claymore Energy Infrastructure Fund
PAYS Paysign Inc
ETB Eaton Vance Tax-Managed Buy-Write Income Fund
RFL Rafael Holdings Inc
BGSF BG Staffing Inc
BAC Bank of America Corp
BCBF Beach Community Bancshares Inc
MDIV First Trust Multi-Asset Diversified Income Index Fund
MCA BlackRock MuniYield California Quality Fund, Inc.
Go

Health Care : Biotechnology | Company profile

Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally administered kinase switch control inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, including glioblastoma multiforme (GBM), and other solid tumors driven by pan-KIT or PDGFR alpha. DCC-3014 is an orally administered, potent and highly selective inhibitor of colony stimulating factor receptor 1 (CSF1R). Rebastinib is an orally administered, potent and selective inhibitor of the TIE2 immunokinase. Rebastinib binds potently into the switch pocket of TIE2, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling.

Closing Price
$36.53
Day's Change
0.51 (1.42%)
Bid
--
Ask
--
B/A Size
--
Day's High
36.72
Day's Low
35.50
Volume
(Heavy Day)
Volume:
1,292,634

10-day average volume:
620,527
1,292,634

Avon Products Q2 loss per share 6 cents vs. loss 9 cents

6:50 am ET August 1, 2019 (MarketWatch)
Print

(END) Dow Jones Newswires

August 01, 2019 06:50 ET (10:50 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.